AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2021
Dec 20, 2021
31100_dirs_2021-12-20_afe77bce-4907-48e1-a827-03d61b0efa6d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-12-16
Reporting Person: Fairman Jeff (VP, Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-16 | Common Stock | M | 4619 | $1.79 | Acquired | 10779 | Direct |
| 2021-12-16 | Common Stock | S | 4619 | $22.50 | Disposed | 6160 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-16 | Stock Option (right to buy) | $1.79 | M | 4619 | Disposed | 2027-05-17 | Common Stock (4619) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 341227 | Indirect |
| Common Stock | 50000 | Indirect |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The shares subject to the option are fully vested and exercisable.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 24